News
XVIPF
30.95
NaN%
--
XVIVO Wins CE Mark for Heart Preservation System, Expanding European Transplant Access
TipRanks · 08/11 12:06
XVIVO Wins Expanded U.S. Enrollment for Heart Transport Trial
TipRanks · 08/03 07:43
XVIVO Perfusion AB Earnings Call Highlights Strong Growth
TipRanks · 07/15 00:07
Xvivo Perfusion Delivers Strong Growth While Ramping Heart R&D Spend
TipRanks · 07/14 06:04
XVIVO Schedules July 14 Call to Present Q2 2026 Interim Results
TipRanks · 06/26 13:33
Xvivo Perfusion’s Record Quarter Signals Growing Momentum
TipRanks · 05/20 07:50
Xvivo Perfusion tech used in 11 Hopital La Pitie-Salpetriere heart transplants
TipRanks · 05/18 12:18
French Approval and Reimbursement Open Nationwide Access to XVIVO Heart Technology
TipRanks · 05/18 12:12
Xvivo Perfusion Earnings Call Highlights Growth And Margins
TipRanks · 04/28 00:14
XVIVO Perfusion AGM Backs Incentive Plan, Withholds Dividend and Expands Financing Flexibility
TipRanks · 04/27 13:41
Xvivo Perfusion AB (publ) GAAP EPS of SEK1.15, revenue of SEK241M
Seeking Alpha · 04/24 11:30
Xvivo Perfusion Delivers Strong Q1 Growth and Advances Heart Preservation Trials
TipRanks · 04/24 06:07
XVIVO Reports Strong Early Trial Results for HOPE Technology in DCD Heart Transplants
TipRanks · 04/22 20:02
XVIVO’s U.S. PRESERVE Trial Shows Strong One-Year Outcomes for Heart Preservation Technology
TipRanks · 04/22 19:32
XVIVO Sets April 24 Call to Present Q1 2026 Interim Report
TipRanks · 04/17 12:05
XVIVO’s Heart Preservation Trial Shows Improved One‑Year Outcomes in European Study
TipRanks · 04/16 14:01
Xvivo Perfusion announces publication of one-year results from NIHP2019 trial
TipRanks · 04/16 13:09
Xvivo Perfusion AB (publ) GAAP EPS of SEK 0.80, revenue of SEK 812.2M
Seeking Alpha · 04/02 12:41
XVIVO Perfusion Calls 2026 AGM, Proposes New Board Members and Incentive Plan
TipRanks · 03/19 12:05
XVIVO Perfusion Updates Board Proposals Ahead of 2026 AGM
TipRanks · 02/20 13:32
More
Webull provides a variety of real-time XVIPF stock news. You can receive the latest news about Xvivo Perfusion through multiple platforms. This information may help you make smarter investment decisions.
About XVIPF
Xvivo Perfusion AB is a Sweden-based medical technology company focused on developing optimized solutions for organ, tissue and cell preservation in connection with transplantation. The Company operates in two segments: Durable goods and Non-Durable goods. The Durable goods segment comprises sale and rental income from XVIVO Perfusion System (XPS) machines. The Non-Durable goods segment implies revenue from the sale of products and services that are solutions and disposable items. The Company’s product portfolio consists of Perfadex, STEEN Solution, XPS, XPS Disposable Kit, XVIVO Lung Cannula Set, XVIVO Organ Chamber, XPS PGM Disposable Sensors and Silicone Tubing Set. The Company markets its products in Europe, Asia, Middle East, and North & South America.